Date：21 July (Wednesday)
Time: 15:40 – 17:10 (GMT+8)
Translational Medicine Lead, Director
Shanghai JiaoTong University, School of Medicine, MD
Paris 7 University, PhD of Oncology
Translational Medicine Lead, Pfizer Development China
Over 10 years industry experiences in oncology/hematology drug discovery and development, from new target identification, in vivo efficacy, translational medicine to clinical development. Focus on translational and companion diagnostic biomarkers.
Homologous recombination deficiency (HRD) assessed by DDR gene mutations is commonly observed in prostate cancer. The dual mechanisms of PARP inhibition induce synthetic lethality in HRD caners. Many efforts have been made to identify the patients more likely response to PARP inhibitor. Two PARP inhibitors, Olaparib and Rucaparib have been approved for treating HR gene mutated mCRPC patients as a single agent. Pathogenic mutations in other HR genes beyond BRCA are warranted to further explore for expanding the repertoire of PARP inhibitors.